A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma

BACKGROUND: The sole effective option for patients with advanced HCC is sorafenib and there is an urgent need to develop new therapeutic approaches. Immunotherapy is a promising option that deserves major investigation. In this open label, single arm clinical trial, we analyzed the effect of a low d...

Descripción completa

Detalles Bibliográficos
Autores principales: Greten, Tim F, Forner, Alejandro, Korangy, Firouzeh, N'Kontchou, Gisele, Barget, Nathalie, Ayuso, Carmen, Ormandy, Lars A, Manns, Michael P, Beaugrand, Michel, Bruix, Jordi
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882353/
https://www.ncbi.nlm.nih.gov/pubmed/20478057
http://dx.doi.org/10.1186/1471-2407-10-209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2882353/
https://www.ncbi.nlm.nih.gov/pubmed/20478057
http://dx.doi.org/10.1186/1471-2407-10-209

Ejemplares similares